News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
273,002 Results
Type
Article (14046)
Company Profile (46)
Press Release (258907)
Multimedia
Podcasts (20)
Webinars (10)
Section
Business (81739)
Career Advice (671)
Deals (11500)
Drug Delivery (54)
Drug Development (43363)
Employer Resources (69)
FDA (5482)
Job Trends (6888)
News (140265)
Policy (11795)
Tag
Academia (1341)
Academic (1)
Accelerated approval (22)
Adcomms (7)
Allergies (64)
Alliances (21435)
ALS (103)
Alzheimer's disease (836)
Antibody-drug conjugate (ADC) (132)
Approvals (5611)
Artificial intelligence (179)
Autoimmune disease (76)
Automation (8)
Bankruptcy (111)
Best Places to Work (5916)
BIOSECURE Act (6)
Biosimilars (48)
Biotechnology (37)
Bladder cancer (77)
Brain cancer (33)
Breast cancer (300)
Cancer (2491)
Cardiovascular disease (175)
Career advice (545)
Career pathing (16)
CAR-T (163)
CDC (17)
Cell therapy (405)
Cervical cancer (11)
Clinical research (37644)
Collaboration (810)
Company closure (2)
Compensation (365)
Complete response letters (18)
COVID-19 (1094)
CRISPR (50)
C-suite (403)
Cystic fibrosis (95)
Data (3453)
Denatured (1)
Depression (72)
Diabetes (236)
Diagnostics (1891)
Digital health (12)
Diversity (3)
Diversity, equity & inclusion (23)
Drug discovery (123)
Drug pricing (114)
Drug shortages (5)
Duchenne muscular dystrophy (136)
Earnings (34087)
Editorial (22)
Employer branding (9)
Employer resources (60)
Events (44004)
Executive appointments (478)
FDA (7011)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (3)
Frontotemporal dementia (13)
Funding (820)
Gene editing (129)
Generative AI (14)
Gene therapy (376)
GLP-1 (462)
Government (2147)
Grass and pollen (1)
Guidances (238)
Healthcare (9186)
HIV (38)
Huntington's disease (22)
IgA nephropathy (56)
Immunology and inflammation (141)
Immuno-oncology (22)
Indications (41)
Infectious disease (1194)
Inflammatory bowel disease (123)
Inflation Reduction Act (9)
Influenza (41)
Intellectual property (125)
Interviews (71)
IPO (6518)
IRA (43)
Job creations (1196)
Job search strategy (486)
Kidney cancer (10)
Labor market (24)
Layoffs (315)
Leadership (10)
Legal (1613)
Liver cancer (47)
Longevity (5)
Lung cancer (322)
Lymphoma (215)
Machine learning (22)
Management (27)
Manufacturing (268)
MASH (108)
Medical device (3291)
Medtech (3302)
Mergers & acquisitions (5358)
Metabolic disorders (628)
Multiple sclerosis (99)
NASH (14)
Neurodegenerative disease (182)
Neuropsychiatric disorders (46)
Neuroscience (1521)
NextGen: Class of 2025 (3088)
Non-profit (3221)
Now hiring (19)
Obesity (257)
Opinion (103)
Ovarian cancer (103)
Pain (87)
Pancreatic cancer (124)
Parkinson's disease (160)
Partnered (16)
Patents (221)
Patient recruitment (231)
Peanut (27)
People (25087)
Pharmaceutical (10)
Pharmacy benefit managers (10)
Phase I (12104)
Phase II (16955)
Phase III (12772)
Pipeline (2650)
Policy (127)
Postmarket research (738)
Preclinical (4863)
Press Release (16)
Prostate cancer (125)
Psychedelics (26)
Radiopharmaceuticals (165)
Rare diseases (485)
Real estate (1680)
Recruiting (26)
Regulatory (9970)
Reports (13)
Research institute (1150)
Resumes & cover letters (146)
Rett syndrome (19)
RNA editing (5)
RSV (26)
Schizophrenia (85)
Series A (140)
Series B (103)
Service/supplier (1)
Sickle cell disease (71)
Special edition (5)
Spinal muscular atrophy (109)
Sponsored (18)
Startups (1563)
Stomach cancer (7)
Supply chain (20)
Tariffs (24)
The Weekly (19)
Vaccines (387)
Venture capital (34)
Weight loss (151)
Women's health (32)
Worklife (4)
Date
Today (7)
Last 7 days (48)
Last 30 days (1089)
Last 365 days (15338)
2025 (15338)
2024 (16939)
2023 (19685)
2022 (22509)
2021 (25138)
2020 (23590)
2019 (21147)
2018 (16071)
2017 (13497)
2016 (12045)
2015 (13926)
2014 (9593)
2013 (7206)
2012 (7669)
2011 (8346)
2010 (7357)
Location
Africa (254)
Alabama (40)
Alaska (3)
Arizona (79)
Arkansas (6)
Asia (13903)
Australia (3018)
California (5347)
Canada (1316)
China (354)
Colorado (182)
Connecticut (288)
Delaware (149)
Europe (38756)
Florida (790)
Georgia (163)
Hawaii (1)
Idaho (16)
Illinois (367)
India (23)
Indiana (216)
Iowa (8)
Japan (240)
Kansas (41)
Kentucky (11)
Louisiana (12)
Maine (7)
Maryland (577)
Massachusetts (4328)
Michigan (70)
Minnesota (168)
Mississippi (2)
Missouri (57)
Montana (9)
Nebraska (12)
Nevada (37)
New Hampshire (22)
New Jersey (1317)
New Mexico (6)
New York (1682)
North Carolina (669)
North Dakota (4)
Northern California (2633)
Ohio (158)
Oklahoma (8)
Oregon (11)
Pennsylvania (1073)
Puerto Rico (6)
Rhode Island (15)
South America (357)
South Carolina (23)
South Dakota (1)
Southern California (2039)
Tennessee (59)
Texas (826)
United States (18960)
Utah (112)
Virginia (103)
Washington D.C. (33)
Washington State (500)
Wisconsin (36)
273,002 Results for "encorps teachers program".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Voyager Throws 30 Staff Overboard After Novartis Sinks Two Programs
Novartis has discontinued two undisclosed programs under its current partership with Voyager, the biotech announced last month. Projects under the deal for spinal muscular atrophy and Huntington’s disease continue to advance.
December 18, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
Saol To Pitch Ultrarare Disease Drug as “Poster Child” for RDEP Program
Saol Therapeutics received a complete response letter for its pyruvate dehydrogenase complex deficiency treatment a week after the FDA unveiled its Rare Disease Evidence Principles program. On Dec. 18, in a Type A meeting, the biotech will attempt to convince the agency that its drug fits perfectly into the framework.
December 9, 2025
·
2 min read
·
Heather McKenzie
Neuroscience
Alkermes Pushes Narcolepsy Program to Phase III With ‘Highly Competitive’ Mid-Stage Data
Alixorexton’s Phase II performance sets it up for late-stage success, according to analysts at Truist Securities. Alkermes expects to launch a global late-stage program early next year for narcolepsy type 2.
November 13, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Optimi Health’s Psilocybin Capsules Selected for Medibank Insurance Program
Australia’s largest private health insurer expands its AUD $10M psychotherapy program to cover psilocybin for Treatment-Resistant Depression, building on earlier MDMA coverage for PTSD
October 6, 2025
·
5 min read
Press Releases
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
December 17, 2025
·
7 min read
Press Releases
From Lab Work to Lesson Planning: The EnCorps Approach to Transforming Bay Area Education with the Help of STEM Professionals
August 6, 2024
·
9 min read
Vaccines
RFK Jr. Looks to Overhaul ‘Broken’ Vaccine Injury Compensation Program
In a post on X, Health Secretary Robert F. Kennedy Jr. alleged that the Vaccine Injury Compensation Program has “devolved into a morass of inefficiency, favoritism, and outright corruption.”
July 29, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Azenta Authorizes $250 Million Share Repurchase Program
December 11, 2025
·
2 min read
Press Releases
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
Company engages Standards Council of Canada; targets ISO 15189 accreditation for early 2026
December 23, 2025
·
3 min read
Government
RFK Jr. Eyes Changes to Vaccine Injury Compensation Program
Kennedy wants to expand the injury compensation program to include COVID-19 vaccines, while also stretching the “statute of limitations” to more than three years.
July 2, 2025
·
2 min read
·
Tristan Manalac
1 of 27,301
Next
